NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Neogenomics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.899 Our recent acquisition of Pathline, a New York State-approved lab based in New Jersey, 00:00:04.899 -- 00:00:09.146 gives us a meaningful presence in the Northeast, which is the number three cancer care 00:00:09.146 -- 00:00:11.707 market in the U.S. 00:00:11.710 -- 00:00:16.177 We believe the addition of Pathline allows us to offer significantly faster turnaround 00:00:16.177 -- 00:00:21.486 times, a larger and relevant New York State-approved test menu, and an enhanced 00:00:21.486 -- 00:00:27.172 physician experience in the Northeast region, where we have historically been underpenetrated. 00:00:27.335 -- 00:00:31.359 The integration continues to proceed according to the plan that we communicated when 00:00:31.359 -- 00:00:36.085 we announced the transaction in March, including the validation of critical turnaround 00:00:36.085 -- 00:00:40.730 time-sensitive assays, which was completed during the third quarter. 00:00:40.730 -- 00:00:44.654 We remain positive about the impact that the acquisition will have in accelerating our 00:00:44.654 -- 00:00:49.800 growth in the Northeast, and we're on track to capture operational efficiencies and synergies 00:00:49.800 -- 00:00:55.564 that we anticipate will be accretive to profitability beginning in 2026. 00:00:55.955 -- 00:01:00.541 Together with our world-class commercial team, we have deep relationships with hospitals, 00:01:00.541 -- 00:01:04.684 cancer centers, and oncologists across the country. 00:01:04.766 -- 00:01:08.531 We're winning the customer experience by enabling precision oncology in the community 00:01:08.531 -- 00:01:14.279 setting, where adoption of next-generation testing has historically lagged behind NCI-designated 00:01:14.279 -- 00:01:16.181 cancer centers. 00:01:...